(Public, OTC:PWRM)
About
Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company has discovered protein biomarker patterns in over 1,500 patient samples that cover a range of diseases.
Three Valuable Patents, Potential FDA Filing
Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases opposed to late stage detection.
They have recently filed for 3 utility patents due to their advances in early stage breast cancer research and are expecting to complete phase II clinical validation trials of their blood serum diagnostics for Alzheimer’s and Parkinson’s disease (NuroPro AD and PD), in the fourth quarter of 2009, followed by completion of filing with the FDA. The medical testing industry is huge and extremely profitable.
Proteomics is the study and analysis of proteins, the fundamental building blocks of the human body. By studying proteins, scientists can understand more fully the functioning of a healthy body and identify the proteins associated with specific diseases. Proteins are not only the building blocks for life; in them, evidence can be found for serious diseases such as cancer, neurodegenerative diseases and other life threatening diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:
- Breast Cancer
- Alzheimer’s Disease
- ALS (Lou Gehrig’s Disease)
- Parkinson’s Disease
- Leukemia
- Gastrointestinal Disease
- Metabolic Syndrome
- Chemotherapeutic Drug Resistance
These discovered and patent-pending biomarkers solve critical challenges facing pharmaceutical and diagnostic companies and are currently being used to design tests to diagnose diseases and discover targets for new drugs to treat the diseases.
Each validated biomarker, pattern, new diagnostic test, or drug target, may have a potential market value from $10 – $100 million plus.
Filing for 3 Utility Patents
On August 20th 2009 Power3 Medical announced that they filed for 3 utility patents due to their significant advances in the technology for their BC-SeraPro serum protein based blood test for diagnosis of EARLY STAGE breast cancer. The significance of these testing methods opposed to mammogram an biopsies is that they are NON-INVASIVE and EARLY DETECTION is through quick blood work rather than detecting tumors that can take many years to form. Currently the standard test for breast cancer is having a mammogram done, however, mammograms usually only pick up tumors that have been growing for 3+ years. BC-SeraPro serum protein based blood test immediately tests for a protein that only cancerous cells release. The FDA has determined that clearance or approval is not necessary for this test by the U.S. Food and Drug Administration because it is used for clinical purposes.The CLIA certification that they have is sufficient for this test to be legally marketed and performed.
